Rubraca (rucaparib) vs Jemperli (dostarlimab)
Rubraca (rucaparib) vs Jemperli (dostarlimab)
Rubraca (rucaparib) is a PARP inhibitor used primarily for the treatment of certain types of ovarian, fallopian tube, or primary peritoneal cancer in patients who have received previous chemotherapy and have specific genetic mutations (BRCA). Jemperli (dostarlimab) is an immune checkpoint inhibitor targeting PD-1, indicated for the treatment of endometrial cancer that has progressed on or after treatment with a platinum-containing regimen, and for solid tumors with mismatch repair deficiency (dMMR). The choice between Rubraca and Jemperli would depend on the patient's specific type of cancer, genetic mutations, previous treatments, and overall health profile, and should be made in consultation with an oncologist who can evaluate the appropriateness of each medication based on these factors.
Difference between Rubraca and Jemperli
| Metric | Rubraca (rucaparib) | Jemperli (dostarlimab) |
|---|---|---|
| Generic name | Rucaparib | Dostarlimab |
| Indications | Ovarian cancer, Fallopian tube cancer, Peritoneal cancer | Endometrial cancer, Solid tumors |
| Mechanism of action | Poly (ADP-ribose) polymerase inhibitor | Programmed death receptor-1 (PD-1) blocking antibody |
| Brand names | Rubraca | Jemperli |
| Administrative route | Oral | Intravenous |
| Side effects | Nausea, fatigue, vomiting, anemia, dysgeusia | Fatigue, musculoskeletal pain, anemia, nausea |
| Contraindications | Hypersensitivity to rucaparib or any of the excipients | Hypersensitivity to dostarlimab or any of the excipients |
| Drug class | PARP inhibitor | Immune checkpoint inhibitor |
| Manufacturer | Clovis Oncology | GlaxoSmithKline (GSK) |
Efficacy
Rubraca (Rucaparib) Efficacy in Gynecological Cancer
Rubraca (rucaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of certain types of gynecological cancers, specifically ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It has shown efficacy in patients with these cancers who have a deleterious BRCA mutation (germline and/or somatic) and have been treated with two or more chemotherapies. Rucaparib has been demonstrated to be effective in inhibiting tumor growth by interfering with the DNA repair process, which is particularly effective in cells with BRCA mutations.
In clinical trials, rucaparib has been associated with improved progression-free survival (PFS) in patients with recurrent ovarian cancer. The ARIEL3 clinical trial, a pivotal phase 3 study, showed that rucaparib significantly improved PFS compared to placebo in patients with platinum-sensitive, recurrent ovarian cancer. Patients with BRCA mutations experienced the most significant benefit, although an improvement in PFS was also observed in the overall study population.
Jemperli (Dostarlimab) Efficacy in Gynecological Cancer
Jemperli (dostarlimab) is a programmed death receptor-1 (PD-1) blocking antibody used in the treatment of endometrial cancer, which is a type of gynecological cancer. It is specifically indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. Dostarlimab works by enhancing the body's immune response against cancer cells.
The efficacy of Jemperli was evaluated in a cohort of the GARNET trial, a multi-center, non-randomized, multiple parallel-cohort study. Patients with dMMR endometrial cancer demonstrated a significant response rate to dostarlimab treatment. The results showed a meaningful proportion of patients achieving complete or partial response, indicating that Jemperli can be an effective treatment option for this patient population. The duration of response for those who benefited from the treatment was also notable, with many patients maintaining their response for six months or longer.
Regulatory Agency Approvals
Rubraca
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Jemperli
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Rubraca or Jemperli today
If Rubraca or Jemperli are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us